Skip to content

XOMA Corporation XOMA Accounts Payable

Accounts Payable at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$5.26M-1.9%
Royalty Pharma logo
Royalty PharmaRPRX
$25.48M-32.3%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$1.1M-54.3%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$6.52M+38.7%
Zymeworks logo
ZymeworksZYME
$30.23M+479%
Xencor logo
XencorXNCR
$7.92M-51.1%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's accounts payable?
XOMA Corporation (XOMA) reported accounts payable of $3.53M in Q1 2026.
How has XOMA Corporation's accounts payable changed year-over-year?
XOMA Corporation's accounts payable increased by 52.4% year-over-year, from $2.32M to $3.53M.
What is the long-term trend for XOMA Corporation's accounts payable?
Over 5 years (2020 to 2025), XOMA Corporation's accounts payable has grown at a 37.1% compound annual growth rate (CAGR), from $456K to $2.21M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.